Insomnia and depression frequently co-occur, creating a formidable challenge for clinical treatment and cognitive recovery. Both conditions are known to exert a heavy toll on cognitive faculties, including attention, working memory, and executive functioning. While CBT-I has been well-documented to improve subjective perceptions of cognition, less is known about its capacity to effect measurable improvements in actual cognitive function across these populations. The recent study seeks to fill this knowledge gap by employing robust objective measures to assess cognitive changes following CBT-I intervention.

This investigation recruited 170 participants drawn from two randomized clinical trials, including patients exclusively experiencing insomnia and those with combined insomnia and depression. These individuals underwent structured 9 to 12-week internet-delivered CBT-I programs, designed to address dysfunctional sleep habits and cognitive distortions associated with insomnia symptoms. The trial’s innovative approach lies in its integration of cognitive assessments derived from the CANTAB battery, a computerized collection of neuropsychological tests renowned for their sensitivity and reliability in detecting subtle changes in cognitive performance.

Pre- and post-treatment cognitive outcomes were meticulously evaluated across parameters measuring sustained attention, working memory, executive planning, and emotional processing. Analytical methods centered on linear regression and mixed-effects modeling permitted nuanced dissecting of the data, accounting for interindividual variability and enabling robust determination of therapy effects. The results illuminated several domains where CBT-I exerted significant positive impacts, reflecting measurable cognitive improvements in the participant group at large.

Among the most notable findings were enhancements in performance on the Rapid Visual Processing task, an indicator of sustained attention and vigilance. Post-treatment data revealed statistically significant increases in correct detections and reductions in missed targets, coupled with a modest decrease in response latency. These markers collectively suggest that CBT-I not only alleviates subjective sleep difficulties but also translates into sharper sustained attention, laying a foundation for broader cognitive restoration.

Further gains emerged in executive function as demonstrated by improved problem-solving accuracy on the Stockings of Cambridge task. Patients displayed enhanced ability to plan and execute complex sequences of moves, reflecting a revitalization in executive control domains critical for adaptive daily functioning. Emotional processing, measured through the Affective Go/No-Go paradigm, also showed gains, with reduced commission errors and affective bias, suggesting CBT-I fosters improved regulation of emotional responses, an essential asset for mental health resilience.

Interestingly, the presence of comorbid depression did not broadly predict diminished cognitive outcomes across most tasks, indicating that insomnia’s cognitive repercussions might be somewhat independent of concurrent mood disturbances. However, a more nuanced deficit was observed in spatial working memory among depressed individuals, evidenced by shorter span length, fewer successful attempts, and prolonged latency on the Spatial Span task. This suggests that depression selectively impairs certain memory circuits, underscoring the complexity of cognitive impairments in co-occurring disorders.

Despite these encouraging improvements, the study found no straightforward associations between the degree of symptom reduction in insomnia or depression and changes in cognitive scores. This dissociation invites further inquiry into the mechanistic pathways through which cognitive enhancements transpire and indicates multifaceted factors beyond symptom alleviation drive neurocognitive recovery. It also accentuates the necessity of longitudinal follow-ups to map the trajectory and sustainability of cognitive gains post-CBT-I.

Methodologically, this study sets a precedent by integrating internet-delivered interventions with rigorous objective cognitive assessments, advancing the feasibility of large-scale cognitive rehabilitation programs. Nevertheless, the authors acknowledge requisite refinements such as controlling for practice effects inherent in repeated cognitive testing and exploring the durability of cognitive benefits over extended timeframes. Such improvements will fortify the evidentiary framework needed to optimize CBT-I protocols tailored for cognitive enhancement.

The implications of these findings bear significant weight for clinical practice and mental health policy. By demonstrating tangible cognitive improvements via CBT-I, clinicians can advocate for early, accessible, and evidence-based behavioral treatments that transcend mere symptom management. Enhanced cognitive function translates into better occupational performance, social engagement, and overall quality of life, particularly for individuals navigating the dual burden of insomnia and depression.

This study also sparks a broader conversation about the neurobiological underpinnings linking sleep, mood regulation, and cognition. The partial independence of cognitive deficits from mood symptom severity challenges simplistic models and encourages interdisciplinary research integrating neuroimaging, neurochemical assays, and behavioral paradigms. Such endeavors promise to unravel the complex circuitry affected by these intertwined disorders, ultimately informing targeted pharmacological and psychotherapeutic interventions.

In conclusion, while the cognitive impairments observed in insomnia with comorbid depression are subtle, the efficacy of CBT-I in enhancing attention, working memory, executive function, and emotional processing emerges as a beacon of hope. The research illuminates a pathway towards objective cognitive recovery, emphasizing that sleep-focused behavioral therapy holds promise beyond symptom relief, extending into domains vital for holistic brain health. As research progresses, the integration of cognitive metrics into clinical workflows will enhance precision treatment and redefine recovery benchmarks.

The journey toward elucidating the full potential of CBT-I in cognitive amelioration is ongoing, and this study marks a pivotal step forward. Future investigations must embrace larger cohorts, more diverse populations, and multimodal assessment strategies to fully characterize the cognitive trajectories of individuals grappling with insomnia and depression. Harnessing these insights will empower clinicians and researchers alike to devise innovative, personalized solutions that restore not only restful sleep but also the cognitive vitality that underpins human thriving.

Subject of Research: Cognitive function in insomnia patients with and without comorbid depression treated with cognitive behavioral therapy for insomnia.

Article Title: Objectively measured cognitive function in insomnia patients with and without comorbid depression treated with cognitive behavioral therapy for insomnia.

Article References:
Tamm, S., Jernelöv, S., Forsell, E. et al. Objectively measured cognitive function in insomnia patients with and without comorbid depression treated with cognitive behavioral therapy for insomnia. BMC Psychiatry 25, 916 (2025). https://doi.org/10.1186/s12888-025-07460-5

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07460-5

Theta burst stimulation, a novel and non-invasive brain stimulation technique, has garnered significant attention in neuroscience due to its ability to modulate neuronal activity with high temporal efficiency. In this latest study, investigators applied TBS to the left dorsolateral prefrontal cortex (DLPFC)—a brain region deeply implicated in executive function and working memory deficits commonly observed in schizophrenia. By focusing on this critical hub, the researchers aimed to uncover whether artificially enhancing cortical excitability translates into measurable improvements in cognitive performance.

The study enrolled one hundred individuals diagnosed with stable chronic schizophrenia. Participants were randomly assigned into two cohorts: an experimental group receiving authentic TBS treatment and a control group subjected to sham stimulation, which mimics the procedure without delivering actual therapeutic pulses. Over a four-week intervention period, both groups underwent systematic cognitive assessments, utilizing standardized instruments such as the Mini-Mental State Examination (MMSE) and the Mattis Dementia Rating Scale Second Edition (MDRS-2). These tools offer nuanced insights into domains including attention, memory, initiation, and conceptual reasoning.

Crucially, the use of functional near-infrared spectroscopy allowed for precise measurement of cerebral blood oxygenation during cognitive tasks. Participants performed a verbal fluency task (VFT)—a challenging exercise that requires active retrieval and generation of words, tapping into the cognitive circuits targeted by TBS. This real-time monitoring of hemoglobin signal fluctuations, particularly in oxygenated and deoxygenated forms, provided a window into the brain’s metabolic responses to the stimulation.

Data analysis revealed a compelling interaction between treatment group and time, demonstrating that the experimental group exhibited significant enhancements across multiple cognitive parameters compared to the sham group. Total scores on both MMSE and MDRS-2 increased, with pronounced gains in domains of attention and memory. Within-subject comparisons further underscored the efficacy of TBS, revealing marked cognitive improvements from baseline to post-treatment. These findings suggest that TBS facilitates neural plasticity mechanisms conducive to restoring impaired cognitive functions.

From a neurophysiological perspective, the fNIRS measurements uncovered notable decreases in deoxyhemoglobin concentrations specifically within channel 47, corresponding anatomically to the left DLPFC. This shift implies enhanced oxygen consumption and cerebral metabolism in the stimulated cortex, corroborating the hypothesis that TBS energizes targeted brain areas by boosting local blood flow and neural activity. Such findings position TBS not merely as a symptomatic intervention but as a modality capable of modulating cortical physiology at a foundational level.

Intriguingly, the investigators also explored demographic influences on treatment response. Regression analyses illuminated age as a significant predictor of cognitive gains measured by MDRS-2 scores, implying that younger patients may derive greater benefit from TBS. This age-dependent effect underscores the necessity of personalized medicine approaches in neuropsychiatric care, prompting future research to delineate optimal treatment windows and dosage schemas tailored to patient characteristics.

This study emerges amid a growing body of literature probing the efficacy of neuromodulation in psychiatric disorders. While transcranial magnetic stimulation (TMS) and its variants have been widely studied, the unique patterned bursts characteristic of TBS appear to induce more robust and enduring synaptic changes. By applying this technique to chronic schizophrenia, a condition traditionally refractory to many treatments, the research breaks new ground in rehabilitation potentials.

Moreover, the integration of fNIRS technology represents a methodological advance, enabling the simultaneous capture of cognitive outcomes and underlying hemodynamic alterations. This dual-layer approach allows for mechanistic insights that bridge behavioral observations and cerebral physiology, offering a comprehensive understanding of how TBS modulates brain function in vivo.

Despite promising results, the authors caution that further large-scale trials and longitudinal follow-ups are essential to validate and extend these findings. The durability of cognitive improvements, potential side effects, and combinatory effects with pharmacotherapy remain important areas for future investigation. Nevertheless, the data offer a hopeful avenue for enhancing the quality of life and functional independence of patients grappling with chronic schizophrenia.

In conclusion, by harnessing the power of theta burst stimulation and advancing neuroimaging techniques, this study marks a pivotal step towards effective cognitive enhancement in schizophrenia. It illuminates how precisely timed bursts of electromagnetic energy can recalibrate disturbed neural circuits, catalyze neurovascular responses, and ultimately uplift cognitive faculties compromised by the disease. As neuroscience inches closer to decoding the complex brain dynamics of schizophrenia, interventions like TBS could herald a new epoch of targeted, evidence-based therapies poised to transform psychiatric care.

Subject of Research: The effect of theta burst stimulation on cognitive function and cerebral blood oxygenation in patients with chronic schizophrenia.

Article Title: Effects of theta burst stimulation on cognitive function and characteristics of blood oxygen alterations based on near-infrared spectroscopy in chronic schizophrenia.

Article References:
Gao, C., Li, G., Zhang, X. et al. Effects of theta burst stimulation on cognitive function and characteristics of blood oxygen alterations based on near-infrared spectroscopy in chronic schizophrenia. BMC Psychiatry 25, 784 (2025). https://doi.org/10.1186/s12888-025-07240-1

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07240-1